International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications : IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders

Despite decades of relevant basic and clinical research, active debate continues about the appropriate extent and duration of benzodiazepine use in the treatment of anxiety and related disorders. The primary basis of the controversy seems to be concern among clinicians, regulators, and the public ab...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical psychopharmacology 1999-12, Vol.19 (6), p.23S-29S
Hauptverfasser: UHLENHUTH, E. H, BALTER, M. B, BAN, T. A, YANG, K
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 29S
container_issue 6
container_start_page 23S
container_title Journal of clinical psychopharmacology
container_volume 19
creator UHLENHUTH, E. H
BALTER, M. B
BAN, T. A
YANG, K
description Despite decades of relevant basic and clinical research, active debate continues about the appropriate extent and duration of benzodiazepine use in the treatment of anxiety and related disorders. The primary basis of the controversy seems to be concern among clinicians, regulators, and the public about the dependence potential and the abuse liability of benzodiazepines. This article reports systematically elicited judgments on these issues by a representative panel of 73 internationally recognized experts in the pharmacotherapy of anxiety and depressive disorders, a panel which was constituted by a multistage process of peer nomination. The criterion for inclusion at each stage was the nomination by at least two peers as one of the "professionally most respected physicians of the world with extensive experience and knowledge in the pharmacotherapy of anxiety and depressive disorders." Sixty-six respondents (90%) completed a comprehensive questionnaire covering a wide range of topics relevant to the therapeutic use of benzodiazepines and other medications that might be used for the same purposes. Overall, the expert panel judged that benzodiazepines pose a higher risk of dependence and abuse than most potential substitutes but a lower risk than older sedatives and recognized drugs of abuse. There was little consensus about the relative risk of dependence and abuse among the benzodiazepines. Differences between benzodiazepines with shorter and longer half-lives in inducing withdrawal symptoms are much less clear during tapered than during abrupt discontinuation. There was little agreement about the most important factors contributing to withdrawal symptoms and failure to discontinue benzodiazepines. The pharmacologic properties of the medication may be the most important contributors to withdrawal symptoms. In contrast, the clinical characteristics of the patient may be the most important contributors to failure to discontinue medication. The experts' judgment seems to support the widespread use of benzodiazepines for the treatment of bona fide anxiety disorders, even over long periods. The experts generally viewed dependence and abuse liability as clinical issues amenable to appropriate management, as for other adverse events related to therapy. However, more definitive clinical research on the remaining controversial issues is urgently needed to promote optimal patient care.
doi_str_mv 10.1097/00004714-199912002-00005
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00004714_199912002_00005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10587281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-82cf7e2eec08f20f3e4d796f10fedd0e72ae47280cdacc03f11e2cb46e4aabf03</originalsourceid><addsrcrecordid>eNptUc1O3DAQtqqiskBfAfnANTB2knXCDaG2rITEhSJukWOPwShrR7Yjsbxz36HOLoU91LJkafz9zMxHCGVwzqAVF5BPJVhVsLZtGQfgxVyqv5AFq8uyEIw_fiUL4IIVIKr2kBzF-ALAKsHrb-SQQd0I3rAF-bNyCYOTyXonBxrTpDfUG4qvI4ZEXyb9tEaXqHc0PWOQI07JKjpFnFE9ujevrXzD0TqMVDpN_YyjY9yoZ79PWaO2ausT6SVdPZzT-71f7bOixhGdRqdwqyT72WawsreDTZv_GdptW3Tw7qnIc6xpCijTrmOTRV4tZqK20QeNIZ6QAyOHiN_f32Py--eP--ub4vbu1-r66rZQFSxT0XBlBHJEBY3hYEqstGiXhoFBrQEFl5g32YDSUikoDWPIVV8tsZKyN1Aek2anq4KPMaDpxmDXMmw6Bt2cYPcvwe4jwW2pztTTHXWc-ryyPeIusgw4ewfIqORggnTKxk8cZzzf8i-43KzP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications : IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>UHLENHUTH, E. H ; BALTER, M. B ; BAN, T. A ; YANG, K</creator><creatorcontrib>UHLENHUTH, E. H ; BALTER, M. B ; BAN, T. A ; YANG, K</creatorcontrib><description>Despite decades of relevant basic and clinical research, active debate continues about the appropriate extent and duration of benzodiazepine use in the treatment of anxiety and related disorders. The primary basis of the controversy seems to be concern among clinicians, regulators, and the public about the dependence potential and the abuse liability of benzodiazepines. This article reports systematically elicited judgments on these issues by a representative panel of 73 internationally recognized experts in the pharmacotherapy of anxiety and depressive disorders, a panel which was constituted by a multistage process of peer nomination. The criterion for inclusion at each stage was the nomination by at least two peers as one of the "professionally most respected physicians of the world with extensive experience and knowledge in the pharmacotherapy of anxiety and depressive disorders." Sixty-six respondents (90%) completed a comprehensive questionnaire covering a wide range of topics relevant to the therapeutic use of benzodiazepines and other medications that might be used for the same purposes. Overall, the expert panel judged that benzodiazepines pose a higher risk of dependence and abuse than most potential substitutes but a lower risk than older sedatives and recognized drugs of abuse. There was little consensus about the relative risk of dependence and abuse among the benzodiazepines. Differences between benzodiazepines with shorter and longer half-lives in inducing withdrawal symptoms are much less clear during tapered than during abrupt discontinuation. There was little agreement about the most important factors contributing to withdrawal symptoms and failure to discontinue benzodiazepines. The pharmacologic properties of the medication may be the most important contributors to withdrawal symptoms. In contrast, the clinical characteristics of the patient may be the most important contributors to failure to discontinue medication. The experts' judgment seems to support the widespread use of benzodiazepines for the treatment of bona fide anxiety disorders, even over long periods. The experts generally viewed dependence and abuse liability as clinical issues amenable to appropriate management, as for other adverse events related to therapy. However, more definitive clinical research on the remaining controversial issues is urgently needed to promote optimal patient care.</description><identifier>ISSN: 0271-0749</identifier><identifier>EISSN: 1533-712X</identifier><identifier>DOI: 10.1097/00004714-199912002-00005</identifier><identifier>PMID: 10587281</identifier><identifier>CODEN: JCPYDR</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>Anti-Anxiety Agents - administration &amp; dosage ; Anti-Anxiety Agents - adverse effects ; Anxiety Disorders - drug therapy ; Anxiety Disorders - psychology ; Benzodiazepines - administration &amp; dosage ; Benzodiazepines - adverse effects ; Biological and medical sciences ; Depression - drug therapy ; Depression - psychology ; Humans ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Substance Withdrawal Syndrome - psychology ; Substance-Related Disorders - psychology ; Surveys and Questionnaires</subject><ispartof>Journal of clinical psychopharmacology, 1999-12, Vol.19 (6), p.23S-29S</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-82cf7e2eec08f20f3e4d796f10fedd0e72ae47280cdacc03f11e2cb46e4aabf03</citedby><cites>FETCH-LOGICAL-c406t-82cf7e2eec08f20f3e4d796f10fedd0e72ae47280cdacc03f11e2cb46e4aabf03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1212212$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10587281$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>UHLENHUTH, E. H</creatorcontrib><creatorcontrib>BALTER, M. B</creatorcontrib><creatorcontrib>BAN, T. A</creatorcontrib><creatorcontrib>YANG, K</creatorcontrib><title>International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications : IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders</title><title>Journal of clinical psychopharmacology</title><addtitle>J Clin Psychopharmacol</addtitle><description>Despite decades of relevant basic and clinical research, active debate continues about the appropriate extent and duration of benzodiazepine use in the treatment of anxiety and related disorders. The primary basis of the controversy seems to be concern among clinicians, regulators, and the public about the dependence potential and the abuse liability of benzodiazepines. This article reports systematically elicited judgments on these issues by a representative panel of 73 internationally recognized experts in the pharmacotherapy of anxiety and depressive disorders, a panel which was constituted by a multistage process of peer nomination. The criterion for inclusion at each stage was the nomination by at least two peers as one of the "professionally most respected physicians of the world with extensive experience and knowledge in the pharmacotherapy of anxiety and depressive disorders." Sixty-six respondents (90%) completed a comprehensive questionnaire covering a wide range of topics relevant to the therapeutic use of benzodiazepines and other medications that might be used for the same purposes. Overall, the expert panel judged that benzodiazepines pose a higher risk of dependence and abuse than most potential substitutes but a lower risk than older sedatives and recognized drugs of abuse. There was little consensus about the relative risk of dependence and abuse among the benzodiazepines. Differences between benzodiazepines with shorter and longer half-lives in inducing withdrawal symptoms are much less clear during tapered than during abrupt discontinuation. There was little agreement about the most important factors contributing to withdrawal symptoms and failure to discontinue benzodiazepines. The pharmacologic properties of the medication may be the most important contributors to withdrawal symptoms. In contrast, the clinical characteristics of the patient may be the most important contributors to failure to discontinue medication. The experts' judgment seems to support the widespread use of benzodiazepines for the treatment of bona fide anxiety disorders, even over long periods. The experts generally viewed dependence and abuse liability as clinical issues amenable to appropriate management, as for other adverse events related to therapy. However, more definitive clinical research on the remaining controversial issues is urgently needed to promote optimal patient care.</description><subject>Anti-Anxiety Agents - administration &amp; dosage</subject><subject>Anti-Anxiety Agents - adverse effects</subject><subject>Anxiety Disorders - drug therapy</subject><subject>Anxiety Disorders - psychology</subject><subject>Benzodiazepines - administration &amp; dosage</subject><subject>Benzodiazepines - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Depression - drug therapy</subject><subject>Depression - psychology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Substance Withdrawal Syndrome - psychology</subject><subject>Substance-Related Disorders - psychology</subject><subject>Surveys and Questionnaires</subject><issn>0271-0749</issn><issn>1533-712X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptUc1O3DAQtqqiskBfAfnANTB2knXCDaG2rITEhSJukWOPwShrR7Yjsbxz36HOLoU91LJkafz9zMxHCGVwzqAVF5BPJVhVsLZtGQfgxVyqv5AFq8uyEIw_fiUL4IIVIKr2kBzF-ALAKsHrb-SQQd0I3rAF-bNyCYOTyXonBxrTpDfUG4qvI4ZEXyb9tEaXqHc0PWOQI07JKjpFnFE9ujevrXzD0TqMVDpN_YyjY9yoZ79PWaO2ausT6SVdPZzT-71f7bOixhGdRqdwqyT72WawsreDTZv_GdptW3Tw7qnIc6xpCijTrmOTRV4tZqK20QeNIZ6QAyOHiN_f32Py--eP--ub4vbu1-r66rZQFSxT0XBlBHJEBY3hYEqstGiXhoFBrQEFl5g32YDSUikoDWPIVV8tsZKyN1Aek2anq4KPMaDpxmDXMmw6Bt2cYPcvwe4jwW2pztTTHXWc-ryyPeIusgw4ewfIqORggnTKxk8cZzzf8i-43KzP</recordid><startdate>19991201</startdate><enddate>19991201</enddate><creator>UHLENHUTH, E. H</creator><creator>BALTER, M. B</creator><creator>BAN, T. A</creator><creator>YANG, K</creator><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19991201</creationdate><title>International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications : IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders</title><author>UHLENHUTH, E. H ; BALTER, M. B ; BAN, T. A ; YANG, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-82cf7e2eec08f20f3e4d796f10fedd0e72ae47280cdacc03f11e2cb46e4aabf03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Anti-Anxiety Agents - administration &amp; dosage</topic><topic>Anti-Anxiety Agents - adverse effects</topic><topic>Anxiety Disorders - drug therapy</topic><topic>Anxiety Disorders - psychology</topic><topic>Benzodiazepines - administration &amp; dosage</topic><topic>Benzodiazepines - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Depression - drug therapy</topic><topic>Depression - psychology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Substance Withdrawal Syndrome - psychology</topic><topic>Substance-Related Disorders - psychology</topic><topic>Surveys and Questionnaires</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>UHLENHUTH, E. H</creatorcontrib><creatorcontrib>BALTER, M. B</creatorcontrib><creatorcontrib>BAN, T. A</creatorcontrib><creatorcontrib>YANG, K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of clinical psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>UHLENHUTH, E. H</au><au>BALTER, M. B</au><au>BAN, T. A</au><au>YANG, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications : IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders</atitle><jtitle>Journal of clinical psychopharmacology</jtitle><addtitle>J Clin Psychopharmacol</addtitle><date>1999-12-01</date><risdate>1999</risdate><volume>19</volume><issue>6</issue><spage>23S</spage><epage>29S</epage><pages>23S-29S</pages><issn>0271-0749</issn><eissn>1533-712X</eissn><coden>JCPYDR</coden><abstract>Despite decades of relevant basic and clinical research, active debate continues about the appropriate extent and duration of benzodiazepine use in the treatment of anxiety and related disorders. The primary basis of the controversy seems to be concern among clinicians, regulators, and the public about the dependence potential and the abuse liability of benzodiazepines. This article reports systematically elicited judgments on these issues by a representative panel of 73 internationally recognized experts in the pharmacotherapy of anxiety and depressive disorders, a panel which was constituted by a multistage process of peer nomination. The criterion for inclusion at each stage was the nomination by at least two peers as one of the "professionally most respected physicians of the world with extensive experience and knowledge in the pharmacotherapy of anxiety and depressive disorders." Sixty-six respondents (90%) completed a comprehensive questionnaire covering a wide range of topics relevant to the therapeutic use of benzodiazepines and other medications that might be used for the same purposes. Overall, the expert panel judged that benzodiazepines pose a higher risk of dependence and abuse than most potential substitutes but a lower risk than older sedatives and recognized drugs of abuse. There was little consensus about the relative risk of dependence and abuse among the benzodiazepines. Differences between benzodiazepines with shorter and longer half-lives in inducing withdrawal symptoms are much less clear during tapered than during abrupt discontinuation. There was little agreement about the most important factors contributing to withdrawal symptoms and failure to discontinue benzodiazepines. The pharmacologic properties of the medication may be the most important contributors to withdrawal symptoms. In contrast, the clinical characteristics of the patient may be the most important contributors to failure to discontinue medication. The experts' judgment seems to support the widespread use of benzodiazepines for the treatment of bona fide anxiety disorders, even over long periods. The experts generally viewed dependence and abuse liability as clinical issues amenable to appropriate management, as for other adverse events related to therapy. However, more definitive clinical research on the remaining controversial issues is urgently needed to promote optimal patient care.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>10587281</pmid><doi>10.1097/00004714-199912002-00005</doi></addata></record>
fulltext fulltext
identifier ISSN: 0271-0749
ispartof Journal of clinical psychopharmacology, 1999-12, Vol.19 (6), p.23S-29S
issn 0271-0749
1533-712X
language eng
recordid cdi_crossref_primary_10_1097_00004714_199912002_00005
source MEDLINE; Journals@Ovid Complete
subjects Anti-Anxiety Agents - administration & dosage
Anti-Anxiety Agents - adverse effects
Anxiety Disorders - drug therapy
Anxiety Disorders - psychology
Benzodiazepines - administration & dosage
Benzodiazepines - adverse effects
Biological and medical sciences
Depression - drug therapy
Depression - psychology
Humans
Medical sciences
Neuropharmacology
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Substance Withdrawal Syndrome - psychology
Substance-Related Disorders - psychology
Surveys and Questionnaires
title International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications : IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A32%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=International%20study%20of%20expert%20judgment%20on%20therapeutic%20use%20of%20benzodiazepines%20and%20other%20psychotherapeutic%20medications%20:%20IV.%20Therapeutic%20dose%20dependence%20and%20abuse%20liability%20of%20benzodiazepines%20in%20the%20long-term%20treatment%20of%20anxiety%20disorders&rft.jtitle=Journal%20of%20clinical%20psychopharmacology&rft.au=UHLENHUTH,%20E.%20H&rft.date=1999-12-01&rft.volume=19&rft.issue=6&rft.spage=23S&rft.epage=29S&rft.pages=23S-29S&rft.issn=0271-0749&rft.eissn=1533-712X&rft.coden=JCPYDR&rft_id=info:doi/10.1097/00004714-199912002-00005&rft_dat=%3Cpubmed_cross%3E10587281%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/10587281&rfr_iscdi=true